<DOC>
	<DOCNO>NCT01020396</DOCNO>
	<brief_summary>The purpose study demonstrate comparable efficacy , safety , tolerability Teva Pharmaceuticals USA 's generic formulation Metronidazole Vaginal Gel , 0.75 % 3M Pharmaceuticals ' MetroGel-VaginalÂ® metronidazole vaginal gel , 0.75 % establish clinical equivalence treatment bacterial vaginosis .</brief_summary>
	<brief_title>Bioequivalence Metronidazole Gel , 0.75 % Treatment Bacterial Vaginosis</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Subjects must provide write informed consent prior study related procedure perform . Female subject must clinical diagnosis bacterial vaginosis , define presence `` clue cell '' &gt; 20 % total epithelia cell microscopic examination saline `` wet mount '' follow criterion : Offwhite ( milky grey ) , thin , homogeneous discharge ; pH vaginal fluid &gt; 4.7 ; positive 10 % KOH `` whiff test '' . Subjects must 18 year age old know medical condition , investigator 's opinion , may interfere study participation . Women child bear potential must negative urine pregnancy test result upon entry study . Subjects must agree abstain sexual intercourse throughout first 7 day study . Following first 7 day , subject must agree use nonlubricated condom engage sexual intercourse . Subjects must willing abstain alcohol ingestion 5 day treatment period 1 day afterward . Subjects must agree refrain use intravaginal product throughout study ( e.g. , douche , feminine deodorant spray , spermicide , lubricate condom , tampon , diaphragm ) . Subjects know suspect infectious cause vulvovaginitis ( e.g . candidiasis , Trichomonas vaginalis , Chlamydia trachomatis , Neisseria gonorrhoeae , active Herpes simplex human papilloma virus , vaginal vulvar condition , investigator 's opinion , would confound interpretation clinical response ) . Subjects Gram 's stain slide Nugent score &lt; 4 . Subjects receive antifungal antimicrobial therapy ( systemic intravaginal ) within 14 day randomization . Subjects take disulfuram within 14 day randomization . Subjects demonstrate previous hypersensitivity reaction metronidazole , either orally topically administer , form parabens . Subjects primary secondary immunodeficiency . Women treatment study period cervical intraepithelial neoplasia ( CIN ) cervical carcinoma . Subjects pregnant , breast feeding , plan pregnancy . Subjects menstruating time diagnosis . Subjects intrauterine device . Concurrent anticoagulation therapy coumadin warfarin . Concurrent use systemic corticosteroid systemic antibiotic . Subjects clinically significant unstable medical disorder , life threaten disease current malignancy . Subjects previously enrol study . Subjects participate another clinical trial take experimental drug within past 30 day . Subjects unwilling unable comply requirement protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Metronidazole</keyword>
	<keyword>Vaginosis</keyword>
</DOC>